AW

Andrew Weisenfeld

Andrew Weisenfeld is a seasoned finance professional with extensive experience in investment banking, currently serving as Managing Partner at MTS Health Partners since January 2008. Prior to this role, Andrew was the Managing Director and co-head of Life Sciences Investment Banking at Banc of America Securities from February 2003 to December 2007, and also held the position of Managing Director at JPMorgan Chase & Co. from 1997 to 2003. Andrew holds an MBA in Finance from The Wharton School, achieved between 1991 and 1993, and a Bachelor of Science degree from Cornell University, completed from 1985 to 1989.

Location

New York, United States

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


CeleCor Therapeutics

CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.


Employees

11-50

Links